Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Dow
Medtronic
Chubb
Farmers Insurance
US Army
US Department of Justice
Fish and Richardson
AstraZeneca
Cerilliant

Generated: August 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Atovaquone pharmaceutical compositions
Abstract:The invention relates to a process for the production of microfluidized particles of atovaquone having improved bioavailability.
Inventor(s): Dearn; Alan Roy (Dartford, GB)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Application Number:09/411,381
Patent Claims: 1. Small particles of atovaquone wherein at least 90% of the particles of atovaquone have a volume diameter in the range 0.1-3 .mu.m.

2. Small particles of atovaquone wherein the particles of atovaquone have been microfluidized.

3. Microfluidized particles of atovaquone wherein at least 90% of the microfluidized particles of atovaquone have a volume diameter in the range 0.1-3 .mu.m.

4. A pharmaceutical composition comprising particles of atovaquone and one or more pharmaceutically acceptable carriers therefor wherein at least 90% of the particles have a volume diameter in the range of 0.1-3 .mu.m.

5. A pharmaceutical composition according to claim 4, wherein the particles are Microfluidized particles.

6. A pharmaceutical composition according to claim 4 or claim 5 in suspension.

7. A pharmaceutical composition according to claim 4 wherein the pharmaceutically acceptable carriers include a suspending agent.

8. A pharmaceutical composition according to claim 4 in suspension wherein the pharmaceutically acceptable carriers include a suspending agent.

9. A pharmaceutical composition according to claim 7, wherein the suspending agent is xanthan gum.

10. A pharmaceutical composition according to claim 8, wherein the suspending agent is xanthan gum.

11. A method for the treatment and/or prophylaxis of protozoal infections in mammals which comprises administering to said mammals an effective amount of particles of atovaquone and one or more pharmaceutically acceptable carrier therefor wherein at least 90% of the particles have a volume diameter in the range of 0.1-3 .mu.m.

12. The method according to claim 11 wherein said protozoal infection is caused by Pneumocystis carinii.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Covington
Medtronic
Teva
Baxter
Chinese Patent Office
Fish and Richardson
Cerilliant
Julphar
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot